Decentralized Dietary UC Pilot Trial

Status Recruiting

Clinical Trial Summary

This study is designed to assess differences in remote and on-site patient study participation in the State of Massachusetts, as well as the significance of dietary interventions and their impact on UC. The study will activate one site with a Principal Investigator who will utilize each subject's local care system (local Gastroenterologist) to collect study data, along with telemonitoring and video visits, to make key study assessments and decisions regarding subjects' progression in the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02357537
Study type	Interventional
Source	Transparency Life Sciences
Contact	Justine States
Phone	(617) 732-9110
Email	dietaryUCTrial@partners.org
Status	Recruiting
Phase	N/A
Start date	January 2015

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04989907` - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Completed	`NCT03494764` - Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares	Phase 2
Recruiting	`NCT03937609` - TITRATE (inducTIon for acuTe ulceRATivE Colitis)	Phase 4
Completed	`NCT00503243` - Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis	Phase 3
Completed	`NCT03606499` - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Completed	`NCT02537210` - Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis	N/A
Active, not recruiting	`NCT02316678` - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics	N/A
Completed	`NCT00488631` - An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3
Completed	`NCT00928681` - A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis	Phase 1
Recruiting	`NCT05242484` - A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 2
Completed	`NCT01036022` - Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis	Phase 2
Recruiting	`NCT03841045` - Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
Active, not recruiting	`NCT05528510` - A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3
Completed	`NCT02825914` - CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)	N/A
Recruiting	`NCT06049017` - A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 2
Completed	`NCT04567628` - Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
Withdrawn	`NCT05999708` - A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants	Phase 1
Recruiting	`NCT05611671` - A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC	Phase 2
Active, not recruiting	`NCT03596645` - A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3
Completed	`NCT03648541` - BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis	Phase 2